PROSTATE-SPECIFIC ANTIGEN VELOCITY (PSAV) RISK COUNT IMPROVES THE SPECIFICITY OF SCREENING FOR CLINICALLY SIGNIFICANT PROSTATE CANCER

Authors


No abstract is available for this article.

Ancillary